SCHEMBL125377

SCHEMBL125377

C[N]CCOC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8641101 0.82
SCHEMBL1851259 0.80
SCHEMBL5953515 0.78
SCHEMBL7537092 0.76
SCHEMBL8376153 0.76 ALDH1A1 (0.41)
SCHEMBL197370 0.74
SCHEMBL15110808 0.74 MPI (0.32)
SCHEMBL12831523 0.69
SCHEMBL15966559 0.69
SCHEMBL251442 0.66 ALDH1A1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 789 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416248-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-12-28 US claimed
WO-2023220219-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2023-11-16 WO claimed
US-20230365560-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-16 US claimed
EP-4244213-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2023-09-20 EP claimed
CN-116745288-A Compounds and uses thereof 福霍恩治疗公司 2023-09-12 CN claimed
US-20230148194-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-05-11 US claimed
US-20230064809-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-03-02 US claimed
EP-3752505-B1 NOVEL SULFONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION HOFFMANN LA ROCHE (CH) 2023-01-11 EP claimed
CN-111484482-B Alkynyl pyrimidine or alkynyl pyridine compound, and composition and application thereof 北京赛特明强医药科技有限公司 2022-06-21 CN claimed
WO-2022103899-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2022-05-19 WO claimed
US-5968923-A ANTIINFLAMMATORY AGENTS, TREATMENT OF NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS PFIZER INC. (US) 1999-10-19 US claimed
US-5741790-A Azetidines PFIZER INC. (US) 1998-04-21 US claimed
EP-0791592-A2 Azetidines Pfizer Limited (GB) 1997-08-27 EP claimed
US-5620974-A ENZYME INHIBITOR, TREATS ACQUIRED IMMUNE DEFICIENCY SYNDROME(AIDS) BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1997-04-15 US claimed
WO-1996005193-A1 (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS PFIZER LIMITED (GB) 1996-02-22 WO claimed
US-5342835-A Antifungal agents based on amides containing a phenyl group RHONE-POULENC AGROCHIMIE (FR) 1994-08-30 US claimed
EP-0385038-B1 ORTHO-SUBSTITUTED PHENYL AMIDINE AND PHENYL GUANIDINE DERIVATIVES AND ANTIDIABETIC OR HYPOGLYCAEMIC AGENTS CONTAINING THEM The Boots Company PLC (GB) 1993-06-02 EP claimed
EP-0385038-A1 Ortho-substituted phenyl amidine and phenyl guanidine derivatives and antidiabetic or hypoglycaemic agents containing them The Boots Company PLC (GB) 1990-09-05 EP claimed
EP-0085286-B1 PARA-SUBSTITUTED 3-PHENOXY-1-CARBONYLAMINOALKYLAMINO-PROPAN-2-OLS HAVING BETA RECEPTOR BLOCKING PROPERTIES Aktiebolaget Hässle (SE) 1986-04-30 EP claimed
EP-0085286-A1 Para-substituted 3-phenoxy-1-carbonylaminoalkylamino-propan-2-ols having beta receptor blocking properties Aktiebolaget Hässle (SE) 1983-08-10 EP claimed